(6) Monoclonal antibody inhibitors of angiopoietin-like protein 3 (ANGPTL3) lower atherogenic lipoproteins by antagonising ANGPTL3-mediated inhibition of lipase activity, thereby promoting lipoprotein clearance. This mechanism is independent of LDL receptor function, which is clinically significant for patients with homozygous FH, where LDL receptor activity is absent or severely impaired. The gene discussed is LDLR; the disease is familial hyperaldosteronism.